Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments
Archives of Cardiovascular Diseases · 2025
DOI: 10.1016/j.acvd.2024.12.012 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archives of Cardiovascular Diseases, 2025. Verfasst von Simon Travers und 4 weiteren Autor:innen. Beteiligte Einrichtung: INSERM UMR-S 1180, Université Paris-Saclay, 91400 Orsay, France; Laboratoire de Biochimie, DMU BioPhyGen, Hôpital Européen Georges Pompidou, AP-HP, 7…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms, Cardiovascular Diseases, Multimodal Imaging. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 183 Literaturangaben.
Abstract (Originalsprache)
Diagnosing cancer therapy-related cardiovascular toxicities may be a challenge. The interplay between cancer and cardiovascular diseases, beyond shared cardiovascular and cancer risk factors, and the increasingly convoluted cancer therapy schemes have complicated cardio-oncology. Biomarkers used in cardio-oncology include serum, imaging and rhythm modalities to ensure proper diagnosis and prognostic stratification of cardiovascular toxicities. For now, troponin and natriuretic peptides, multimodal cardiovascular imaging (led by transthoracic echocardiography combined with cardiac magnetic resonance or computed tomography angiography) and electrocardiography (12-lead or Holter monitor) are cornerstones in cardio-oncology. However, the imputability of cancer therapies is sometimes difficult to assess, and more refined biomarkers are currently being studied to increase diagnostic accuracy. Advances reside partly in pathophysiology-based serum biomarkers, improved cardiovascular imaging through new technical developments and remote monitoring for rhythm disorders. A multiparametric omics approach, enhanced by deep-learning techniques, should open a new era for biomarkers in cardio-oncology in the years to come.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- INSERM UMR-S 1180, Université Paris-Saclay, 91400 Orsay, France; Laboratoire de Biochimie, DMU BioPhyGen, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France. Electronic address: simon.travers@aphp.fr.
- INSERM U1086 ANTICIPE, Biology-Research Building, UNICAEN, Normandie University Group, 14000 Caen, France; Department of Pharmacology, Biology-Research Building, PICARO Cardio-Oncology Programme, Caen-Normandy Universit…
- Cardiovascular Medicine, Yale School of Medicine, 06510 New Haven CT, United States of America. Electronic address: laure.baldassarre@yale.edu.
- CIC-1901, Department of Pharmacology, Hôpital Pitié-Salpêtrière, AP-HP, Sorbonne Université, INSERM, 75013 Paris, France. Electronic address: joeelie.salem@gmail.com.
- Cardiology Department, Institut Mutualiste Montsouris, 75014 Paris, France. Electronic address: mariana.mirabel@imm.fr.
Zitieren
APA
Travers, S., Alexandre, J., Baldassarre, L. A., Salem, J. E., & Mirabel, M. (2025). Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments. Archives of Cardiovascular Diseases. https://doi.org/10.1016/j.acvd.2024.12.012
Vancouver
Travers S, Alexandre J, Baldassarre LA, Salem JE, Mirabel M. Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments. Archives of Cardiovascular Diseases. 2025. doi:10.1016/j.acvd.2024.12.012
BibTeX
@article{Travers2025,
author = {Travers, Simon and Alexandre, Joachim and Baldassarre, Lauren A and Salem, Joe Elie and Mirabel, Mariana},
title = {Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments},
journal = {Archives of Cardiovascular Diseases},
year = {2025},
doi = {10.1016/j.acvd.2024.12.012}
}
EUVIMED